Posted by Michael Wonder on 10 Jun 2024
SpliSense receives FDA fast track designation for SPL84 for the treatment of cystic fibrosis
29 May 2024 - SpliSense today announced that the US FDA has granted fast track designation to SPL84 for cystic fibrosis.
SPL84 is the Company's lead antisense oligonucleotide product for the treatment of patients with cystic fibrosis carrying the 3849+10 kilobase (Kb) C->T splicing mutation in the transmembrane conductance regulator gene.
